Muromonab CD3

Drug Profile

Muromonab CD3

Alternative Names: Anti-CD3 monoclonal antibody OKT3; Monoclonal antibody OKT3; OKT-3; OKT3 antibody; Orthoclone OKT-3

Latest Information Update: 11 Jul 2011

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunosuppressants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart transplant rejection; Liver transplant rejection; Renal transplant rejection
  • Discontinued Cancer; Renal cancer

Most Recent Events

  • 14 Oct 2002 A case report has been added to the adverse events section
  • 12 Feb 1999 Launched for Renal transplant rejection in Argentina (IV-injection)
  • 31 Dec 1998 Discontinued - Clinical-Phase-Unknown for Renal cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top